ENCER

Company Overview

Snapshot

Founded in June 2019 by Orna Goldberg, ENCER operates with 1–10 employees. The company has raised $250,000 across one funding round. In April 2025, ENCER ceased to operate.

Business overview

ENCER is an emerging pharmaceutical company focused on the research, development, and commercialization of proprietary products designed to address the side effects of cancer treatment. The company has developed a clinically approved homeopathic solution, Encer+, for cancer treatment-related fatigue. This non-chemical product is intended for use in conjunction with conventional cancer treatments without causing additional side effects, serving the healthcare and life sciences sectors, specifically targeting patients in oncology.

Strategic signal

The cessation of operations in April 2025 for ENCER indicates a significant strategic shift, moving the company from an active pharmaceutical developer to a non-operational entity. This development signals to investors and innovation teams that the company's prior initiatives in homeopathic cancer treatment solutions have concluded, marking a definitive end to its market presence and product development efforts.

Company Intelligence Q&A

What is ENCER's primary focus?

ENCER is dedicated to the research, development, and commercialization of proprietary products designed to address the side effects of cancer treatment, specifically focusing on a homeopathic solution for cancer treatment-related fatigue.

When was ENCER founded?

ENCER was founded in June 2019.

What is the status of ENCER?

ENCER is currently non-active, having ceased to operate in April 2025.

What product does ENCER offer?

ENCER offers Encer+, a clinically approved homeopathic solution for cancer treatment-related fatigue.

What is ENCER's primary sector?

ENCER operates in the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Drugs Discovery & Development.